导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.39% | 939/4773 |
| 近一周 | -1.30% | 1987/5465 |
| 近一月 | -1.99% | 1415/5421 |
| 近一季 | -4.73% | 1877/5231 |
| 近半年 | 4.51% | 870/4920 |
| 近一年 | 12.77% | 926/4394 |
| 近两年 | 58.26% | 1283/2954 |
| 近三年 | 38.61% | 800/2253 |
| 成立以来 | 72.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.50% 1826/4961 |
17.88% 1445/5312 |
- - |
- - |
| 2025 | 19.11% 2250/4813 |
-0.34% 2210/3635 |
2.31% 1654/4076 |
14.23% 2937/4524 |
2.27% 1018/4813 |
| 2024 | 16.05% 851/3463 |
3.30% 601/2808 |
-0.36% 749/3014 |
14.07% 2052/3129 |
-1.16% 1607/3463 |
| 2023 | -14.02% 1579/2656 |
1.07% 1650/2280 |
-4.70% 1260/2385 |
-3.94% 1017/2515 |
-7.07% 2041/2655 |
| 2022 | -20.96% 1003/2207 |
-14.89% 1009/1919 |
7.86% 421/2016 |
-13.59% 928/2113 |
-0.36% 1599/2208 |
| 2021 | -5.23% 973/1822 |
-2.42% 639/1255 |
4.44% 886/1330 |
-8.85% 1159/1466 |
2.03% 722/1822 |
| 2020 | 46.08% 214/1250 |
-7.69% 561/1028 |
16.60% 428/1067 |
16.00% 180/1164 |
17.00% 142/1184 |
| 2019 | 46.93% 129/1092 |
26.49% 405/739 |
1.57% 120/788 |
5.10% 165/850 |
8.82% 284/918 |
| 2018 | - - |
- - |
- - |
0.04% 164/660 |
-12.75% 482/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发沪深300指数增强C VS. 长安沪深300非周期A(740101) |